Jin Rong Jie·2025-12-19 03:11Core Viewpoint - Fosun Pharma has entered into a strategic collaboration with Clavis Bio to jointly develop innovative therapies based on cutting-edge targets nominated by Clavis Bio [1] Group 1: Collaboration Details - The collaboration will last for a period of five years, during which up to four targets will be selected and advanced for preclinical development each year [1] - Clavis Bio holds exclusive licensing options for global development, production, and commercialization outside of mainland China and Hong Kong, while Fosun Pharma retains exclusive rights within these regions [1] Group 2: Financial Implications - If Clavis Bio exercises its option for a specific collaboration project, Fosun Pharma could receive up to $362.5 million in payments, which includes non-refundable option fees, development milestone payments, and sales milestone payments [1] - Additionally, Fosun Pharma will receive a percentage-based royalty on net sales of the products involved in the collaboration within the licensed territories [1]